Cargando…
Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists
Medications for type 2 diabetes (T2DM) offer a promising path for discovery and development of effective interventions for dementia syndromes. A common feature of dementia syndromes is an energy failure due to reduced energy supply to neurons and is associated with synaptic loss and results in cogni...
Autores principales: | Yassine, Hussein N., Solomon, Victoria, Thakral, Angad, Sheikh‐Bahaei, Nasim, Chui, Helena C., Braskie, Meredith N., Schneider, Lon. S., Talbot, Konrad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940606/ https://www.ncbi.nlm.nih.gov/pubmed/34647685 http://dx.doi.org/10.1002/alz.12474 |
Ejemplares similares
-
WHITE MATTER CHANGE NEAR CEREBRAL MICROBLEEDS AFTER MTBI INVOLVES AGE AND SEX DEPENDENT COGNITIVE DECLINE
por: Irimia, Andrei, et al.
Publicado: (2022) -
Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
por: Arellanes, Isabella C., et al.
Publicado: (2020) -
The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States
por: Aranda, María P., et al.
Publicado: (2023) -
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease
por: Yassine, Hussein N., et al.
Publicado: (2016) -
The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)